Teva, forging ahead with new strategy, inks biosimilar deal with Spain's mAbxience

As Teva advances its Pivot to Growth strategy under CEO Richard Francis, the company is making good on its pledge to beef up its biosimilar pipeline through outside deals.

The Israeli-American drugmaker has unveiled a fresh in-licensing accord with Spain’s mAbxience to chip in on an investigational biosimilar spanning “multiple oncology indications,” according to a Thursday release.